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Comparative Prediction of Cardiac Events
by Wall Motion, Wall Motion Plus Coronary
Flow Reserve, or Myocardial Perfusion Analysis
A Multicenter Study of Contrast Stress Echocardiography
Nicola Gaibazzi, MD, PHD,* Fausto Rigo, MD,† Valentina Lorenzoni, MSC,‡
Sabrina Molinaro, PHD,‡ Francesco Bartolomucci, MD,§ Claudio Reverberi, MD,*
Thomas H. Marwick, MD, PHD
Parma, Mestre-Venice, Pisa, and Bari, Italy; and Cleveland, Ohio
O B J E C T I V E S This study sought to determine whether the increasing difﬁculty of assessing wall
motion (WM), Doppler coronary ﬂow reserve on the left anterior descending coronary artery (CFR-LAD),
and myocardial perfusion (MP) during stress echocardiography (SE) was justiﬁed by increasing
prognostic information in patients with known or suspected coronary artery disease.
B A C KG ROUND The use of echocardiographic contrast agents during SE permits the assessment
of both CFR-LAD and MP, but their relative incremental prognostic value is undeﬁned.
METHOD S This study followed a multicenter cohort of 718 patients for 16 months after high-dose
dipyridamole contrast SE for evaluation of known or suspected coronary artery disease. The ability of WM,
CFR-LAD, and MP to predict cardiac events was studied by multivariable models and risk reclassiﬁcation.
R E S U L T S Abnormal SE was detected as a reversible WM abnormality in 18%, reversible MP defect
in 27%, and CFR-LAD 2 in 38% of subjects. Fifty cardiac events occurred (annualized event rate 6.0%).
A normal MP stress test had a 1-year hard event rate of 1.2%. The C-index of outcomes prediction based
on clinical data was improved with MP (p  0.001) and WM/CFR-LAD (p  0.037), and MP (p  0.003)
added to clinical and WM data. Net risk reclassiﬁcation was improved by adding MP (p  0.001) or
CFR-LAD (net reclassiﬁcation improvement p  0.001) in addition to clinical and WM data. The model
including clinical data, WM/CFR-LAD, and MP performed better than that without MP did (p  0.012).
CONC L U S I O N S Themultiparametric assessment ofWM, CFR-LADandMPduring stress testing in patients
with known or suspected coronary artery disease is feasible. Contrast SE allowed better prognostication,
irrespective of the use of CFR-LAD or MP. The addition of either CFR-LAD or MP assessment to standard WM
analysis and clinical parameters yielded progressively higher values for the prediction of cardiac events and may
be required in today’s intensively treated patients undergoing SE, because their average low risk of future cardiac
events requires methods with higher predictive sensitivity than that available with standalone WM
assessment. (J Am Coll Cardiol Img 2013;6:1–12) © 2013 by the American College of Cardiology Foundation
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2harmacological stress echocardiography (SE)
using wall motion (WM) analysis is an es-
tablished technique for the detection and prog-
nostication of coronary artery disease (CAD)
1,2). Indeed, the prediction of cardiac events with
E is incremental to clinical, rest echocardio-
raphic, and angiographic parameters (3). Assess-
ent of long-term outcome of contrast SE is
mportant because this test may identify both
igh-risk patients who would benefit from inva-
ive intervention and lower-risk patients in whom
dditional procedures and intensive medical
ollow-up are not required. The use of echocar-
See page 13
diographic contrast agents has improved
the accuracy of SE (4). Although the risk
of events is low in patients without WM
abnormalities, an at-risk subgroup can be
identified with myocardial perfusion (MP)
defects alone (5–8). Contrast SE also
facilitates the measurement of the left
anterior descending coronary artery flow
reserve (CFR-LAD) using transthoracic
Doppler, and CFR-LAD shows incre-
mental value to WM analysis (9–11).
Whether these 3 parameters, sequentially
assessed during the same stress test, pro-
vide incremental, complementary, or re-
dundant prognostic information remains
to be determined. In the present study, we
sought to determine the association be-
tween contrast high-dose dipyridamole
SE (DipSE) findings with future cardiac
events in a large, prospective, contempo-
rary, and multicenter cohort of patients
(n  718) with suspected or known CAD and to
define the potential complementary value of WM,
CFR-LAD, and MP analysis.
M E T H O D S
Study population. Between January 2009 and
March 2011, we enrolled 752 patients undergoing
contrast DipSE for evaluation of chest pain with
suspected or known CAD at 3 Italian hospitals:
University Hospital, Parma (n  470), Umberto I
ospital, Mestre-Venice (n  161), and Andria
Hospital, Bari (n  121). All patients met the
following inclusion criteria: 1) stable chest pain;
2) absence of absolute contraindications to dipyridam-
se
ry
rior
s
n
y
alityole; 3) absence of known allergy to sulphonamide- ncontaining products; 4) enrollment in a follow-up
program. Exclusion criteria were: 1) inadequate acous-
tic window; 2) severe valvular or congenital heart
disease; 3) suspected pregnancy; 4) significant comor-
bidity reducing life expectancy to 1 year; 5) unwill-
ingness to give informed consent.
Traditional risk factors for CAD, including ar-
terial hypertension (blood pressure 140/90 mm Hg
or use of antihypertensive medication), hyperlipid-
emia (total cholesterol 200 mg/dl or treatment
with lipid-lowering medications), current or prior
smoking, diabetes mellitus (fasting glucose level
126 mg/dl or the need for insulin or oral hypo-
glycemic agents), history of CAD, and a family
history of CAD were recorded. The study was
conducted in accordance with the institutional re-
view board standards of all participating centers.
Contrast stress echocardiography. This protocol is
ummarized in Figure 1 and has been already
escribed in detail elsewhere (12). Briefly,
-dimensional echocardiography, 12-lead electro-
ardiography, and blood pressure monitoring were
erformed in combination with high-dose dipyri-
amole (0.84 mg/kg over 6 min) in accordance with
standard protocol (1). Transthoracic stress echo-
ardiography was performed with commercially
vailable ultrasound machines (iE33 Philips Ultra-
ound, Andover, Massachusetts) using multifre-
uency phased-array probes (S5), second harmonic,
nd low-mechanical index power modulation tech-
ology. Apical 2-, 3-, and 4-chamber views were
btained both for WM and MP; a modified
-chamber view for CFR-LAD imaging was inte-
rated into the imaging sequence. Contrast WM,
FR-LAD, and MP were sequentially assessed
sing the same probe (S5) by activation of the
ppropriate preset. The left ventricle (LV) was
ivided into 17 segments (13). Repeated 0.5-ml
onoVue boluses (Bracco Imaging Italia SRL, Mi-
an, Italy) were administered at rest and at peak
tress, followed by low-power (mechanical index 
.10) contrast-specific imaging for MP and a dif-
erent preset (LV opacification, with harmonic
maging and mechanical index  0.27) for contrast
M analysis; the standard 2-dimensional preset
as resumed (WM monitoring) after microbubbles
ere cleared. For MP assessment, flash-replenishment
equences were acquired, both in the continuous (40
rames/s) or triggered mode (end-systolic at every
ardiac cycle). Just before administration of the
ontrast bolus, the low mechanical index setting was
ctivated and optimized for gain and power so thatA B B R E V I A T I O N S
A N D A C R O N YM S
CAD coronary artery disea
CFR-LAD Doppler corona
flow reserve on the left ante
descending coronary artery
CI confidence interval
DipSE dipyridamole stres
echocardiography
HR hazard ratio
LV left ventricle
MImyocardial infarction
MPmyocardial perfusion
MPDmyocardial perfusio
defect(s)
SE stress echocardiograph
WMwall motiono signal was detectable from the myocardium;
g
a
.
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3after 0.5-ml SonoVue bolus, the start of acquisition of
the MP flash-replenishment sequences was approxi-
mately 10 s after peak video intensity, this delay
being used to avoid saturation.
Coronary flow in the mid-distal LAD was sought
in the low parasternal long-axis or modified
2-chamber view, guided by color Doppler flow
mapping. Color-coded blood flow from the LAD
was visualized both at rest and peak stress using
contrast enhancement (SonoVue, 0.2-ml intrave-
nous bolus); flow velocities were measured at base-
line and at peak stress (before aminophylline injec-
tion). For both color Doppler flow mapping and
pulsed-wave velocity measurements, the standard
setting for CFR-LAD was adjusted after contrast
bolus by lowering the mechanical index down to
0.1. At each time point, the 3 best profiles of peak
diastolic Doppler flow velocities were measured,
and the results were averaged.
Interpretation of test results. Segmental WM was
raded as follows: normal  1; hypokinetic  2;
kinetic  3; and dyskinetic  4. Reversible isch-
emia was defined as the occurrence of a stress-
induced new dyssynergy or worsening of rest hypo-
kinesia in 1 segment.
Abnormal perfusion post-dipyridamole was as-
signed if1 segment was not fully replenished 1.5 s
after the end of the flash. Rest perfusion was
deemed abnormal if replenishment occurred 4 s
after the flash impulse. Myocardial perfusion defect
(MPD) was scored as fixed or reversible based on its
presence at rest. LV segments were excluded from
Figure 1. Schematic of the Contrast SE Protocol
AMINO  aminophylline; contrast-LAD  Doppler sampling of the
damole; MP  myocardial perfusion; SE  stress echocardiographyMP interpretation if they were not clearly visualizeddue to shadowing artifacts or low ultrasound pen-
etration. Coronary blood flow velocity reserve was
defined as the ratio between hyperemic and basal
peak diastolic coronary flow. CFR-LAD 2.0 was
considered normal (1,9–11).
The assessment of the contrast SE was per-
formed at each center by consensus of 2 investiga-
tors. Readers used a binary score of normal/
abnormal for all of the 3 assessed SE parameters,
whatever the image quality of the test; if at least 1
reader evaluated at least 1 parameter as “uninter-
pretable,” the patient was excluded from the study.
Intraobserver and interobserver agreement data for
WM, MP, and CFR-LAD have previously been
published for each participating center (12,14), but
a specific assessment of interobserver variability
with an expert external reader (T.H.M.) on 20
randomly selected study cases was also performed
for both wall motion abnormalities (WMA) and
MP, and reported as a percentage with a corre-
sponding kappa value.
Follow-up and deﬁnition of study endpoints. Follow-up
information was obtained from the start of the
study until June 2011. Outcomes were determined
from patient interview at the outpatient clinic,
hospital chart reviews, and telephone interviews
with the patient, close relatives, or the referring
physician. Data were prospectively collected at least
3 months after the contrast SE examination (me-
dian: 16.5 months, interquartile range: 8 to 22
months). Death, nonfatal MI, and acute coronary
syndrome requiring urgent revascularization were
-distal left anterior descending artery; contrast-WM  contrast wall mmid otion; DIP  dipyri-registered as clinical events. Coronary revasculariza-
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4tion (surgery or percutaneous intervention) was also
recorded. Overall mortality was considered to avoid
misclassification of the cause of death (15). MI was
defined by typical symptoms and electrocardio-
graphic and cardiac enzyme changes. Follow-up
data were analyzed for the prediction of the primary
combined endpoint of death, nonfatal MI, and
acute coronary syndrome requiring urgent revascu-
larization (total cardiac events) and, secondarily, for
death or nonfatal MI (hard events).
Statistical analysis. Continuous variables are ex-
pressed as mean SD, whereas categorical data are
given as numbers and percentages. Patients under-
going test-driven coronary revascularization (de-
fined as revascularization within 90 days) were
censored at the time of their procedure, which was
not considered a cardiac event. Only the first event
was taken into account.
SURVIVAL ANALYSIS AND MULTIVARIABLE
MODELING. Event-free survival and the rates of
ard and total cardiac events were estimated with
aplan-Meier curves, and the log-rank test was
sed to compare survival curves between groups.
nivariable and multivariable Cox proportional
azard models were used to identify features asso-
iated with both hard and total cardiac events.
ariable selection for the multivariable models was
ased on clinical knowledge and/or association with
 0.1 at univariable analysis. A ratio of 10
vents per degree of freedom was maintained.
To assess the value of SE measurements over
linical parameters for event prediction, SE vari-
bles were sequentially included in multivariable
odels with relevant clinical predictors. Overall,
hi-square and likelihood ratio tests were used to
ompare the prognostic value of the clinical model
ith models comprising SE parameters. C-statistics
nd Akaike information criterion were used to
ompare model strengths.
RECLASSIFICATION. The impact of contrast SE
variables on reclassification of patient risk with respect
to total cardiac events was determined using net
reclassification improvement (16). For each patient,
the predicted risk of total cardiac events was deter-
mined based on each model, followed by assessment
of the impact of additional information on patient
reclassification; net reclassification improvement rep-
resents the net number of patients with improved
reclassification, summing reclassification in patients
with events and patients without events. We exam-
ined reclassification using thresholds of 3% and 10%
total cardiac events per year to define low-, cintermediate-, and high-risk groups. We considered
these thresholds appropriate, based on the total car-
diac event rate of 6% per year in our study.
Due to the small number of hard events, model
comparison and reclassification analysis were lim-
ited to the composite endpoint. Statistical analyses
were performed using standard software (STATA
release 10 and R 2.11, StataCorp, College Station,
Texas). A p value0.05 was considered statistically
significant for all the analyses.
R E S U L T S
Patient characteristics. The test was deemed unin-
terpretable for at least 1 of the 3 tested parameters
in 29 patients (4%), who were excluded. Of the 723
patients remaining, 5 (0.7%) were lost to follow-up,
leaving a final study cohort of 718 patients.
Approximately one-third of the patients had a
history of CAD, and those without this diagnosis
had a high prevalence of risk factors. Ischemia
(reversible WMA) was present in 18% of patients,
compared with 27% with inducible MPD and 38%
with reduced CFR-LAD (2.0). Patients with
positive MP imaging had 2.6  1.5 reversible
defects, and only 28 had 2 segments with revers-
ible perfusion defects. A complete overview of the
baseline characteristics of the study group is illus-
trated in Table 1.
The interobserver agreement of DipSE with an
external blinded expert reader (T.H.M.) on 20
randomly selected study cases was 80% (k  0.60)
for MP and 95% (k  0.86) for WM.
Outcomes. Fifty events (7.0%) occurred during
follow-up, including death in 8 patients (1.1%),
nonfatal infarction in 20 (2.8%), and acute coronary
syndrome requiring urgent revascularization in 22
(3.1%); 85 patients (11.8%) undergoing test-driven
revascularization (within 3 months of SE) were cen-
sored at that time. Annual hard and total cardiac event
rates were, respectively, 2.8% and 6.0% in the entire
population, 2.1% and 4.1% in patients without known
CAD, 4.5% and 10.4% in patients with known CAD.
Prediction of composite endpoint. Patients with any
SE abnormality showed a higher annual event rate
than did subjects with normal SE (10.8% vs 2.1%,
p  0.001). The few patients with abnormal WM/
FR-LAD but normal MP findings had low event
ates (2.2%/year). In contrast, patients with abnor-
al MP alone (15.9%/year) or with both abnormal
P and WM/CFR-LAD (20%/year) showed
igher annual event rates. Figure 2 shows the total
ardiac event rate in relation to the positivity of each
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5contrast SE variable and relevant combinations,
whereas Figure 3A shows the related Kaplan-Meier
event-free survival curves.
The features associated with total cardiac events
are shown in Table 2. Of the baseline patient data,
hypercholesterolemia, diabetes mellitus, known
CAD, and aspirin therapy at the time of testing
predicted total cardiac events. Reduced LV ejection
fraction at rest echo and all contrast SE variables
(reversible WMA, reversible MPD, CFR-LAD
2, and the combination of reversible WMA or
CFR-LAD 2) predicted events. CFR-LAD 2
(hazard ratio [HR]: 2.25, 95% confidence interval
[CI]: 1.21 to 4.17) and MPD (HR: 5.97, 95% CI:
3.02 to 11.78) remained predictive of total events in
the multivariate analysis of the 3 SE variables,
whereas WMA did not (p  0.37).
The incremental value of WMA, CFR-LAD,
Table 1. Clinical Characteristics and Echocardiographic
Findings in 718 Recruited Patients
Age, yrs 65 11
Sex, M/F 442/276
Risk factors and patient history
Hypertension* 485 (68)
Hypercholesterolemia† 422 (59)
Current smokers 168 (23)
Diabetes mellitus 200 (28)
Family history of CAD 238 (33)
Reduced ejection fraction, LVEF 50% 172 (24)
Known CAD 226 (31)
Previous myocardial infarction 135 (19)
Previous revascularization 221 (31)
Medications
ACE inhibitors/ARB 481 (67)
Statin 435 (61)
Beta-blockers 459 (64)
ASA 468 (65)
Contrast stress-echocardiography
Patients with reversible WMA 129 (18)
Patients with CFR-LAD 2 275 (38)
Patients with reversible MPD 198 (27)
Patients with reversible WMA and
CFR-LAD 2
83 (12)
Patients with reversible WMA or
CFR-LAD 2
321 (45)
Patients with reversible WMA or
CFR-LAD 2 or reversible MPD
351 (49)
Values are mean  SD or n (%). *Blood pressure 140/90 mm Hg or
treatment of hypertension. †Total cholesterol >200 mg/dl or treatment of
hypercholesterolemia.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor block-
ers; ASA  acetylsalicylic acid; CAD  coronary artery disease; CFR-LAD 
Doppler coronary ﬂow reserve on the left anterior descending coronary
artery; LVEF  left ventricular ejection fraction; MPD  myocardial perfusion
defects; WMA  wall motion abnormalities.PD, and their combination for prediction of total cardiac events in a Cox proportional hazards
odel is summarized in Table 3. The clinical
odel (based on diabetes, hyperlipidemia, and
nown CAD) had a C-index of 0.667. The
ddition of WMA significantly increased the
-index to 0.70, whereas the addition of CFR-
AD exceeded this (C-index: 0.739), and MPD
arried even more predictive power (C-index:
.795). The combination of the 3 contributed a
inor increment in predictive power.
Table 4 summarizes the incremental benefit of
dding each layer of complexity of imaging to the
odel, including the reclassification index. Either
M/CFR-LAD or MPD variables significantly
dded prognostic value to the model based on
linical data (respectively, p  0.037 and p  0.001
or C-index comparison), whereas only MPD sig-
ificantly added to the model comprising clinical
ata and WMA (p  0.003 for C-index compari-
on). These data indicate that the model including
oth WM/CFR-LAD and MPD along with clin-
cal data performed significantly better than the
odel with WMA/CFR-LAD and clinical data
model 5 vs. model 3, p  0.012 for C-index
omparison).
Classification groups were set at annual total
ardiac event rates of 0% to 3%, 3% to 10%, and
10%. Whereas WMA alone was not able to
ignificantly reclassify risk incremental to clinical
ata (p  0.81), the addition of either WMA/
FR-LAD 2 (p  0.001) or MPD (p  0.001)
ignificantly improved risk reclassification over clin-
cal data. An improvement in risk reclassification
as also detected for the model including WM/
FR-LAD and clinical parameters with respect to
he model including only WMA and clinical data
p  0.001). The addition of MPD to clinical
arameters also provided an improvement in risk
rediction in comparison to models with clinical data
nd WMA (p  0.001) or WMA/CFR-LAD 2
p  0.021). Models including both the WM/CFR-
AD and MPD along with clinical parameters im-
roved risk prediction with respect to models consid-
ring WMA (p  0.001) or WM/CFR-LAD (p 
.025) in addition to clinical variables, whereas there
as no difference compared with the model including
linical parameters and MPD only (p  0.54).
Prediction of hard events. Of baseline patient data,
he only variables associated with hard cardiac
vents were sex (HR: 2.766, 95% CI: 1.04 to 7.35),
iabetes mellitus (HR: 2.64, 95% CI: 1.22 to 5.73),
nd hypercholesterolemia (HR: 3.36, 95% CI: 1.27
o 8.92). Reduced LV ejection fraction at rest echo
and MP has an event, i MP
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6(HR: 2.3, 95% CI: 1.7 to 5) and all contrast SE
variables—reversible WMA (HR: 4.74, 95% CI:
2.15 to 10.48), reversible MPD (HR: 4.44, 95% CI:
2.05 to 9.61), CFR-LAD 2 (HR: 3.03, 95%
CI: 1.38 to 6.68), and the combination of reversible
WMA or CFR-LAD2 (HR: 4.18, 95% CI: 1.76 to
9.95)—were univariate predictors of hard events.
None of the C-indices for univariable prediction of
hard events was significantly different from the others.
Hard event-free survival differed significantly
between patients depending on the SE results (Fig.
3B). The annual event rate with any abnormal
contrast SE finding was 3-fold increased compared
with normal findings (4.7% vs. 1.4%, p  0.001),
whereas this was not the case selectively for abnor-
mal dipyridamole-induced WMA (0.8% per year)
or CFR-LAD 2 (2.2% per year). Patients with an
abnormal MPD, both without or with WMA or
CFR-LAD 2, showed a higher annual event rate
(isolated MPD: 3.9%, MPD  WM/CFR-LAD:
9.8%, log-rank p  0.001).
D I S C U S S I O N
In the current study, both comparison of multivari-
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
Ab
no
rm
al 
C
No
rm
al 
CF
R
Ab
no
rm
al 
WM
 or
 CF
R
No
rm
al 
WM
 an
d C
FR
Ab
no
rm
al 
WM
No
rm
al 
WM
Ov
er
all
 Po
pu
lat
ion
c 1-Year Event Rate
nt rate in the overall population and classiﬁed based on stress-echocard
coronary ﬂow reserve on the left anterior descending coronary artery (C
using myocardial perfusion (MP) data increased both sensitivity and sp
the highest incidence of events. Note that the same events are shared b
t is counted in both the “abnormal WM” and “abnormal MP” subgroups.able models and risk reclassification analysis dem-onstrate that the addition of CFR-LAD and MP
during SE progressively improve prognostication of
future total cardiac events over usual WM assessment
and clinical data. Importantly, to make WM assess-
ment as repeatable and accurate as possible, WM was
assessed using LV cavity opacification. The superiority
of MP and CFR-LAD in this context is important, as
it emphasizes that the results are unlikely to change
with alterations to the WM analysis.
Myocardial perfusion versus wall motion. Existing di-
agnostic studies of WM and MP have emphasized
superiority of specificity with the former, and sen-
sitivity with the latter (12,17). Generally, MP is
more useful to diagnose less severe (50% to 70%) and
less diffuse CAD. From a prognostic standpoint, the
predictive value of a negative test is very high with
both negative WM and MP (5,18). The SE literature
has shown MP to add incremental prognostic value to
WM in the prediction of major events using the
dobutamine-atropine protocol (5,6) and dipyridamole
protocol (19), as well as a number of studies showing
an improvement of composite endpoints (7,8,20). The
practical problem in the incorporation of these data
into practice has been that MP and CFR-LAD have
Ab
no
rm
al 
WM
 or
 CF
R<
2 a
nd
 M
PD
Iso
lat
ed
 M
PD
Ab
no
rm
al 
MP
No
rm
al 
MP
aphy ﬁndings. Compared with standard wall motion (WM) analysis,
LAD) data added more sensitivity but less speciﬁcity for prediction of
ity, with normal MP predicting the lowest incidence of events and a
erlapping subgroups; for example, if a patient with abnormal WM
D  myocardial perfusion defect(s).FR
Figure 2. Total Cardia
Total cardiac 1-year eve iogr
the addition of Doppler FR-
cardiac events, whereas eciﬁc
positive MP predicting y ovremained technically challenging, in particular at the
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 1 , 2 0 1 3
J A N U A R Y 2 0 1 3 : 1 – 1 2
Gaibazzi et al.
Prognostic Indices During Stress Echo
7Normal SE
Abnormal SE
0 200 400 600 800
0.70
0.75
0.80
0.85
0.90
0.95
1.00
Normal
Only WMA/CFR<2
Only MPD
WMA/CFR<2 + MPD
Follow-up (days)
0 200 400 600 800
0.70
0.75
0.80
0.85
0.90
0.95
1.00
Normal SE
Abnormal SE
Normal
Only WMA/CFR<2
Only MPD
WMA/CFR<2 + MPD
0 200 400 600 800
0.70
0.75
0.80
0.85
0.90
0.95
1.00
0 200 400 600 800
0.80
0.85
0.90
0.95
1.00
A
B
Figure 3. Total Cardiac and Hard Event-Free Survival Rates
(A) Total cardiac event-free survival rates classiﬁed by positivity of at least 1 contrast SE variable (either WMA, CFR-LAD 2, or MPD) or by possible combinations
of contrast SE variables. Patients testing positive for both MPD and the combination of WMA/CFR-LAD 2 had the worst event-free survival (log-rank p value
0.001). (B) Cardiac hard event-free survival rates classiﬁed by positivity of at least 1 contrast SE variable (either wall motion abnormality [WMA], CFR-LAD 2,
or MPD) or by possible combinations of contrast SE variables. Abbreviations as in Figures 1 and 2.
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8high heart rate typical of the dobutamine-atropine
protocol.
It has already been demonstrated that Doppler
CFR-LAD measurement during DipSE can addi-
ionally stratify cardiac risk; the results of our study
uild on the previous work, showing the incremental
enefit of CFR-LAD to be only a little less than MP
or the prediction of future cardiac events relative to
MA. The C value was not significantly higher in
odels substituting MPD with combined WM/
FR-LAD, although they were higher when MPD
as added to WM/CFR-LAD. These results support
he contention that at least 1 of the 2 additional
arameters (CFR-LAD or MP) should be used in
ddition to WM assessment for better stratification of
isk during DipSE, and their additive value is clinically
articularly useful when no WMA can be elicited by
he stressor.
Approximately 140 patients had abnormal WM/
CFR-LAD with normal MP, most because of a
reduced CFR-LAD and normal WM, among
whom abnormal but borderline (1.9 to 2.0) CFR-
LAD results were present in 66 patients. The
and Selected Multivariable Cox Regression Analysis of the 3 SE V
Univariate
Harrell C-Index (95% CI) HR
risk factors
0.528 (0.45–0.61) 1.01
0.550 (0.48–0.62) 1.62
D 0.493 (0.42–0.56) 1.01
0.514 (0.45–0.58) 1.04
ia 0.601 (0.54–0.66) 2.44
0.595 (0.52–0.67) 2.28
0.557 (0.50–0.62) 1.49
0.514 (0.48–0.55) 0.74
CAD/revascularization 0.595 (0.52–0.67) 1.99
0.558 (0.49–0.62) 1.72
ation 0.580 (0.50–0.65) 1.96
stress test
0.599 (0.54–0.66) 2.81
0.562 (0.50–0.63) 1.56
0.537 (0.47–0.60) 1.36
0.554 (0.49–0.62) 1.60
0.583 (0.51–0.65) 2.25
0.654 (0.59–0.72) 3.58
0.589 (0.52–0.66) 3.01
0.735 (0.67–0.80) 6.57
2 0.667 (0.60–0.73) 4.27
V  cardiovascular; HR  hazard ratio; MI  myocardial infarction; SE  stresssignificance of this pattern is unknown; we suspect athat it may relate to error in CFR measurement, but
decreased CFR could also be due to microvascular
impairment/endothelial dysfunction secondary to hy-
pertension/diabetes/hypercholesterolemia. The clini-
cal and prognostic meaning of this pattern cannot be
addressed in this study design and requires a cross-
sectional study with another functional marker of
CAD, such as fractional flow reserve.
Previous SE studies and outcome risk stratiﬁcation. In
he largest published studies regarding the prognos-
ic value of dipyridamole SE, the annual rate of
ard events is typically close to 3% for patients with
uspected CAD and close to 6% for patients with
nown CAD (2,3). In our population, which has
imilar clinical characteristics and a similar ratio of
uspected versus known CAD, the annual hard
vent rate in the entire population was lower
2.8%), similar to the hard event rate of patients
ith suspected CAD in the previous studies. Sev-
ral reasons could explain a lower event rate in our
tudy, but the most intriguing hypothesis is that our
tudy enrolled patients from current cardiology
ractice (between 2009 and 2011), whereas the
bles for the Prediction of Total Cardiac Events
Multivariate
% CI) p Value HR (95% CI) p Value
9–1.04) 0.387
7–3.02) 0.127
6–1.83) 0.965
4–1.99) 0.913
7–4.68) 0.007
9–4.01) 0.004
9–2.82) 0.217
7–2.05) 0.562
3–3.51) 0.016
1–3.25) 0.095
9–3.51) 0.024
6–5.80) 0.005
5–2.87) 0.151
2–2.58) 0.337
7–2.95) 0.128
8–3.95) 0.005
9–6.45) 0.000 2.25 (1.21–4.17) 0.01
2–5.61) 0.001 0.72 (0.36–1.46) 0.37
7–11.75) 0.000 5.97 (3.02–11.78) 0.001
7–8.06) 0.000
cardiography; other abbreviations as in Table 1.Table 2. Univariable aria
(95
Demographics/cardiac
Age, yrs (0.9
Sex (0.8
Family history of CA (0.5
Smoking habit (0.5
Hypercholesterolem (1.2
Diabetes mellitus (1.2
Hypertension (0.7
Obesity (0.2
CV history
Previous MI/known (1.1
Previous MI (0.9
Previous revasculariz (1.0
Therapy at the time of
ASA (1.3
Beta-blockers (0.8
ACE (0.7
Statins (0.8
Stress echo
Reduced LVEF, 50% (1.2
CFR-LAD 2 (1.9
WMA (1.6
MPD (3.6
WMA or CFR-LAD  (2.2bove-mentioned landmark studies used historical
in T
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9databases of patients enrolled since 1995, when
medical therapy was less intensive than at present.
In our study, approximately two-thirds of patients
were on therapy shown to have prognostic benefit
(Table 1). In particular, 104 (77%) of the 135
patients with a prior MI were on therapy with
high-dose/high-potency statins, defined as atorvas-
tatin 40 mg or rosuvastatin 20 mg.
Clinical application. MP assessment was performed
using repeated contrast boluses and flash-replenishment
sequences, both with end-systolic triggering and in real
time (Fig. 4, Online Videos 1, 2, 3, and 4).
Table 3. The Multivariable Models Alternatively Incorporating
WM/CFR-LAD and MPD Risk Stratiﬁed Total Cardiac Events B
Model 2 Through Model 5
Total Card
Model 1—
Clinical Parameters
Only
Model
Clinical Param
WMA
HR 95% CI p Value HR 95% CI
Hypercholesterolemia 2.03 (1.04–3.96) 0.04 1.97 (1.01–3.84
Diabetes 1.89 (1.06–3.36) 0.03 1.76 (0.98–3.14
Previous MI/
known CAD
1.84 (1.04–3.23) 0.04 1.63 (0.92–2.91
CFR
WMA 2.40 (1.27–4.55
MPD
WMA or CFR-LAD 2
AIC 588.28 583.9
Harrell C-index 0.667 (0.596–0.738) 0.703 (0.633
Global chi-square 6.39
p value for likelihood
ratio test
(compared with
Model 1)
0.011
AIC  Akaike information criterion; WM  wall motion; other abbreviations as
Table 4. Summary of Model Comparisons for Total Cardiac Even
Summary Table for Model Comparison p Value
Clinical parameters only model (Model 1) vs.
Clinical data  WMA
Clinical data  WMA/CFR-LAD 2
Clinical data  MPD
Clinical parameters  WMA (Model 2) vs.
Clinical data  WMA/CFR-LAD 2
Clinical data  WMA  MPD
Clinical data  MPD
Clinical parameters  WMA/CFR-LAD (Model 3) vs.
Clinical data  WMA/CFR-LAD 2  MPD
Clinical parameters  MPD (Model 4) vs.
Clinical data  MPD  WMA/CFR-LAD 2
Risk reclassiﬁcation is also shown, based on NRI. Bold values are statistically si
NRI  net reclassiﬁcation improvement; other abbreviations as in Table 1.Although continuous infusion would have been the
ideal technique for analyzing contrast replenish-
ment following a high mechanical index impulse
and could have led to an even higher prognostic
value of MP, we found that the bolus technique
resulted in much lower contrast use, still producing
satisfying results for visual analysis. Our group and
others have shown that the analysis of contrast
replenishment from small bolus injections of con-
trast is effective for detecting coronary artery dis-
ease, with accuracy values that exceed that of
scintigraphic imaging (12,21).
ch of the Tested SE Parameters (WM, WM/CFR, MPD) or Comb
r Than Clinical Parameters Only (Model 1) and Progressively B
vents Multivariable Cox Models
rs 
Model 3—
Clinical Parameters 
WMA/CFR <2
Model 4—
Clinical Parameters 
MPD
Clin
WM
Value HR 95% CI p Value HR 95% CI p Value HR
0.05 1.92 (0.98–3.77) 0.06 1.72 (0.88–3.37) 0.10 1.69
0.06 1.72 (0.96–3.09) 0.07 1.80 (1.01–3.20) 0.04 1.75
0.10 1.65 (0.94–2.92) 0.08 1.52 (0.86–2.69) 0.21 1.46
0.01
5.72 (3.18–10.3) 0.00 4.11
3.87 (2.04–7.32) 0.00 1.99
570.31 555.33
72) 0.739 (0.673–0.805) 0.795 (0.734–0.855) 0
19.97 34.95
0.001 0.001
ables 1 and 2
rediction, Based on Harrell C-Index and Likelihood Ratio Test
r Harrell C-Index Difference p Value for Likelihood Ratio
0.148 0.012
0.037 <0.001
<0.001 <0.001
0.242 Not feasible
0.004 <0.001
0.003 Not feasible
0.012 <0.001
0.766 0.059
ant.Ea ination of
ette etter From
iac E
2—
ete
Model 5—
ical Parameters 
A/CFR <2  MPD
p 95% CI p Value
) (0.86–3.31) 0.13
) (0.98–3.11) 0.06
) (0.82–2.59) 0.20
)
(2.10–8.05) 0.00
(0.96–4.12) 0.07
0 553.78
–0.7 .799 (0.739–0.858)
38.51
0.001ts P
fo Test NRI
0.810
0.001
<0.001
0.001
<0.001
<0.001
0.025
0.542
gniﬁc
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10Although MP has a strong evidence base, its
widespread application has been limited by techni-
cal complexity in its application and some subjec-
tivity in its interpretation. MP is exquisitely sensi-
tive for mild CAD, but problems with artifacts limit
its interpretation in the absence of WM assessment;
nonetheless, in our study, the number of segments
with reversible MPD (in patients with abnormal
MP) was 2.6  1.5, and in this abnormal MP
ubgroup, only 28 patients had 2 segments with
eversible MPD. This emphasizes the robustness of
tudy findings. Moreover, although mid-apical seg-
ents for each coronary territory are usually inter-
retable, several perfusion assessments are incom-
lete because of limited feasibility in the basal
yocardial segments.
Although exercise testing might be considered
he best protocol in which to compare WM with
ther parameters, as it offers maximal stress and
ssessment of functional capacity, we selected phar-
acological stress on the basis of the inability of
any patients to exercise effectively. In addition,
mage degradation with exercise would make mea-
urements of other parameters (MP, CFR-LAD)
articularly difficult. The exclusion of parasternal im-
ges allowed direct comparison of all modalities in
xactly the same view, but may have disadvantaged
M analysis when the apical window was poor.
Although 1 advantage of measuring CFR-LAD
a Flash-Replenishment Stress Perfusion Sequence
nce in apical 4-chamber (A) and 3-chamber (B) views; from left to rig
ﬂash. At the 2-s cutoff point for normal myocardial replenishment a
lenishment; wall motion is instead normal in the apical segments, bu
ess (Online Videos 1, 2, 3, and 4). The white-ﬁlled arrow points to an
f a ﬁxed perfusion defect when using contrast-speciﬁc settings.s that it is inherently quantitative, it should be recognized that there is a degree of subjectivity in
he selection of tracings used to calculate the ratio
mong different measured velocities. Stenoses, tor-
uosity, and bridges can all lead to regional variation
f measurements, both at rest and stress; conse-
uently, the ratios can vary across the threshold of 2
n the same patient. The use of a contrast bolus
nhances color Doppler signals from the mid-distal
AD, with feasibility being almost 100%. How-
ver, PW Doppler envelopes after contrast tend to
e noisy, and experience is needed to obtain mea-
urable diastolic peak velocities.
Although CFR-LAD and MP do not appear to
ave clear synergistic value in our study (only the
ddition of MPD to WM/CFR-LAD increased
isk prediction assessment, and not the opposite),
e demonstrated that the use of at least 1 of the 2
arameters improved prognostic stratification. The
ossibility of implementing WM, MP, and CFR-
AD during the same test may very well be a reason
or greater use of vasodilators (dipyridamole or
denosine) for pharmacological SE in the future.
In this study, we used total cardiac events (n 
0) to be an appropriate and statistically robust
ndpoint. Censoring patients who undergo revas-
ularization following a diagnostic test, as we did in
he current study, is widely used to analyze prog-
ostic studies, because of the potential confounding
ffect of revascularization. This excludes the highest
end-systolic frame before destructive ﬂash (see ﬂash icon), post-
ess, both the apical and lateral segments (arrows) show incom-
unted (akinesia) in the lateral mid-basal segments both at rest
erolateral subendocardial scar, often shown as hyperechogenicFigure 4. Example of
Stress perfusion seque ht,
ﬂash, 2 s, and 4 s after t str
plete microbubble rep t bl
(not shown) and at str infisk patients from the study, reducing the total
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11number of hard events to 28, and possibly under-
estimating the discriminative power of the tests. In
addition, censoring patients undergoing early revas-
cularization may have led to a more pronounced
underestimation of the value of WMA, because its
presence and extent is used as an indication for
revascularization (differential treatment selection
bias).
C O N C L U S I O N S
Contrast SE allows for accurate risk stratification in
patients with suspected or known ischemic heart
disease. The multiparametric assessment of WM,
CFR-LAD, and MP during stress testing is feasible,
identifies patients at increased risk for cardiac eventselderly. Eur Heart J 2008;29:377–85.
1
1
1
1
American Societyand separates them from those with normal findings
who are at much lower risk. A normal MP stress test
was the most reassuring result for patients undergoing
SE, with a 1-year hard event rate of 1.2% and a total
cardiac event rate of 2.1%. The addition of either
CFR-LAD measurement or MP assessment to stan-
dard WM analysis and clinical parameters yielded
progressively higher values for the prediction of total
cardiac events and may be required in today’s inten-
sively treated patients undergoing SE, because their
average low risk of future cardiac events requires
methods with higher predictive sensitivity than is
available with stand-alone WM assessment.
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For accompanying videos and their legends,
please see the online version of this paper.
